Pre-made Dinutuximab benchmark antibody ( Whole mAb, anti-Ganglioside GD2 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Dinutuximab biosimilar, Whole Mab: Anti-Ganglioside GD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Dinutuximab (Ch14.18, tradename Unituxin) and Dinutuximab beta (tradename Qarziba) are monoclonal antibodies used as a second-line treatment for children with high-risk neuroblastoma. Each antibody is made of both mouse and human components and targets glycolipid GD2, expressed on neuroblastoma cells and on normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. They differ in that dinutuximab is manufactured using mouse cells, and dinutuximab beta is manufactured using hamster cells. The dosing regime differs, and dinutuximab is given in combination with granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), while dinutuximab beta can be given alone.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-146-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Dinutuximab biosimilar, Whole Mab: Anti-Ganglioside GD2 therapeutic antibody
INN Name	Dinutuximab
Target	Ganglioside GD2
Format	Whole mAb
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:AB:CD/4tuk:HL
Year Proposed	2013
Year Recommended	2014
Companies	National Cancer Institute (USA);New Approaches to Neuroblastoma Therapy Consortium;St. John of God Foundation;United Therapeutics Corporation
Conditions Approved	Neuroblastoma
Conditions Active	Small cell lung cancer
Conditions Discontinued	Malignant melanoma
Development Tech	na